Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database study

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA A Cancer J Clin. 2022;72(1):7–33.
   PubMed Web of Science ®Google Scholar
• Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol. 2021;157:103194.
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology (NCCN guidelines) non-small cell lung cancer, version 3.2022 [cited 2022 Jun 16]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Google Scholar
• NCCN clinical practice guidelines in oncology (NCCN guidelines) thyroid carcinoma version 2.2022 [cited 2022 Jun 16]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf
   Google Scholar
• Hess LM, Krein PM, Haldane D, et al. Biomarker testing for patients with advanced/metastatic nonsquamous NSCLC in the United States of America, 2015 to 2021. JTO Clin Res Rep. 2022;3(6):9.
   Google Scholar
• Parikh R, Hess LM, Esterberg E, et al. Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer. Thyroid Res. 2022;15(1):2.
   PubMed Web of Science ®Google Scholar
• Sireci N, Krein P, Hess L, et al. Biomarker testing patterns in patients with stage IV non-small cell lung cancer (NSCLC) in the US community-based oncology practice setting. Boston (MA): ASCO Quality Care; 2021.
   Google Scholar
• Robert NJ, Nwokeji ED, Espirito JL, et al. Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the US oncology network community practices. Wolters Kluwer Health; 2021.
   Google Scholar
• Desai K, Hooker G, Gilbert K, et al. Real-world trends in costs of next generation sequencing (NGS) testing in US setting. Wolters Kluwer Health; 2021.
   Google Scholar
• Normanno N, Apostolidis K, de Lorenzo F, et al. Cancer biomarkers in the era of precision oncology: addressing the needs of patients and health systems. Semin Cancer Biol. 2022;84:293–301.
   PubMed Web of Science ®Google Scholar
• Butler AM, Nickel KB, Overman RA, et al. IBM MarketScan research databases. In: Sturkenboom M, Schink T, editors. Databases for pharmacoepidemiological research. Cham: Springer International Publishing; 2021. p. 243–251.
   Google Scholar
• HHS. Human subject regulations decision charts: 2018 requirements; 2020 [cited 2021 Feb 3]. Available from: https://www.hhs.gov/ohrp/regulations-and-policy/decision-charts-2018/index.html#c1
   Google Scholar
• Nordstrom BL, Simeone JC, Malley KG, et al. Validation of claims algorithms for progression to metastatic cancer in patients with breast, non-small cell lung, and colorectal cancer. Front Oncol. 2016;6:18.
   PubMed Web of Science ®Google Scholar
• Whyte JL, Engel-Nitz NM, Teitelbaum A, et al. An evaluation of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data. Med Care. 2015;53(7):e49–e57.
   PubMed Web of Science ®Google Scholar
• Statistics UBoL. Consumer price index; 2020. Available from: https://www.bls.gov/cpi/
   Google Scholar
• Korytowsky B, Radtchenko J, Nwokeji ED, et al. Understanding total cost of care in advanced non-small cell lung cancer pre-and postapproval of immuno-oncology therapies. Am J Manag Care. 2018;24(20 Suppl):S439–S447.
   PubMed Web of Science ®Google Scholar
• Zhang X, Beachler DC, Masters E, et al. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States. J Manag Care Spec Pharm. 2022;28(2):255–265.
   PubMed Web of Science ®Google Scholar
• Lin S, Luo S, Gu D, et al. First-line durvalumab in addition to etoposide and platinum for extensive-stage small cell lung cancer: a US-based cost-effectiveness analysis. Oncologist. 2021;26(11):e2013–e2020.
   PubMed Web of Science ®Google Scholar
• NCI. Financial burden of cancer care; 2022.
   Google Scholar
• Aguilar-Serra J, Gimeno-Ballester V, Pastor-Clerigues A, et al. Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer. Expert Rev Pharmacoecon Outcomes Res. 2022;22(4):637–646.
   PubMed Web of Science ®Google Scholar
• Peng Y, Zeng X, Peng L, et al. First-line atezolizumab for metastatic NSCLC with high PD-L1 expression: a United States-based cost-effectiveness analysis. Adv Ther. 2021;38(5):2447–2457.
   PubMed Web of Science ®Google Scholar
• Berger A, Edelsberg J, Chung K, et al. Healthcare (HC) utilization and costs in patients (pts) with newly diagnosed metastatic thyroid cancer (mTC). J Clin Oncol. 2007;25(18_suppl):17082.
   Web of Science ®Google Scholar
• Rivas AM, Nassar A, Zhang J, et al. ThyroSeq® V2. 0 molecular testing: a cost-effective approach for the evaluation of indeterminate thyroid nodules. Endocr Pract. 2018;24(9):780–788.
   PubMed Web of Science ®Google Scholar
• Mihaylova B, Briggs A, O'Hagan A, et al. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20(8):897–916.
   PubMed Web of Science ®Google Scholar
• Cantoni E, Ronchetti E. A robust approach for skewed and heavy-tailed outcomes in the analysis of health care expenditures. J Health Econ. 2006;25(2):198–213.
   PubMed Web of Science ®Google Scholar
• Trogan G. What do payers want in oncology diagnostics? Insights from a national survey of top commercial and medicare health plans. Am Health Drug Benefits. 2011;4. Available from: https://www.ahdbonline.com/issues/2011/august-2011-vol-2014-no-2014-special-issue/2790-article-2790?page=2010,2012
   Google Scholar
• Hsiao SJ, Mansukhani MM, Carter MC, et al. The history and impact of molecular coding changes on coverage and reimbursement of molecular diagnostic tests: transition from stacking codes to the current molecular code set including genomic sequencing procedures. J Mol Diagn. 2018;20(2):177–183.
   PubMed Web of Science ®Google Scholar
• Zou D, Ye W, Hess LM, et al. Diagnostic value and cost-effectiveness of next generation sequencing-based testing for treatment of patients with advanced/metastatic non-squamous non-small cell lung cancer in the US. J Mol Diagn. 2022;24(8):901–914.
   PubMed Web of Science ®Google Scholar
• NCHS. High-deductible health plan enrollment among adults aged 18–64 with employment-based insurance coverage; 2018.
   Google Scholar